Ascendis Pharma (ASND) PT Raised to $201 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $250.17 --0%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Cantor Fitzgerald analyst Alethia Young raised the price target on Ascendis Pharma (NASDAQ: ASND) to $201.00 (from $185.00) while maintaining a Overweight rating.
You May Also Be Interested In
- National Stock Exchange of India (NSE:IN) PT Raised to INR1,975 at Macquarie
- EnPro Industries (NPO) PT Raised to $440 at JPMorgan
- Alteogen Inc (196170:KS) PT Lowered to KRW300,000 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
